

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 February 2025 (13.02.2025)



(10) International Publication Number
WO 2025/034702 A1

(51) International Patent Classification:

A61K 31/501 (2006.01) A61P 31/00 (2006.01)
A61K 45/06 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2024/041036

(22) International Filing Date:

06 August 2024 (06.08.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/531,175	07 August 2023 (07.08.2023)	US
63/543,420	10 October 2023 (10.10.2023)	US
63/618,783	08 January 2024 (08.01.2024)	US

(71) Applicant: **REVOLUTION MEDICINES, INC.**
[US/US]; 700 Saginaw Drive, Redwood City, CA 94063 (US).

(72) Inventors: **JIANG, Jingjing**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **SINGH, Mallika**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **WANG, Zhengping**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **WANG, Zhican**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **YANG, Yu, Chi**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **BAO, Lei**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **DUA, Richa**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US).

(74) Agent: **BELLIVEAU, Michael J.** et al.; Clark & Elbing LLP, 101 Federal Street, 15th Floor, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: RMC-6291 FOR USE IN THE TREATMENT OF RAS PROTEIN-RELATED DISEASE OR DISORDER



(57) Abstract: The disclosure features methods of treating RAS disorders using Compound (A), or a pharmaceutically acceptable salt thereof. The disclosure also features methods of treating RAS disorders (e.g., cancer) including combinations of Compound (A), or a pharmaceutically acceptable salt thereof, and additional therapeutic agent. Compound (A) is a compound having the structure (A).

WO 2025/034702 A1